// App-Quantinova.ai

: Modified release hydrocortisone capsules (MRHC, Efmody) improve control of congenital adrenal hyperplasia (CAH) on a lower glucocorticoid dose than standard treatment

Researchers

Presenter

  • Aled Rees

Principal Investigators

  • Deborah P Merke

  • Wiebke Arlt

  • Aude Brac De La Periere

  • Angelica Linden Hirschberg

  • Anders Juul

  • Ashwini Mallappa

  • John D. C. Newell-Price

  • Colin Graham Perry

  • Alessandro Prete

  • Nicole Reisch

  • Monica Stikkelbroeck

  • Philippe A Touraine

  • Helen Coope

  • John Porter

  • Richard John M Ross

Medical Centers

  • Cardiff University, Cardiff, United Kingdom

  • NIH Clinical Center, Bethesda, MD, United States

  • University of Birmingham, Surrey, United Kingdom

  • Louis Pradel Hospital, Lyon, France

  • Karolinska Institutet, Sweden

  • Rigshospitalet, Copenhagen, Denmark

  • AstraZeneca, Gaithersberg, MD, United States,

  • University of Sheffield, Sheffield, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Endokrinologie, Nephrologie und weitere Sektionen - Medizinische Klinik und Poliklinik IV - Campus Innenstadt, München, Germany

  • Radboud University, Nijmegen, Netherlands

  • University Hospitals Pitié Salpêtrière - Charles Foix, Rheumatology, Paris, France

  • Diurnal, United Kingdom

Locations

  • United Kingdom

  • United States

  • France

  • Sweden

  • Denmark

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Congenital disorder

  • Genetic Disorder

Disease

  • Congenital adrenal hyperplasia

Biomarkers

  • N/A

Drug/Treatment

  • Hydrocortisone

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Prednisolone

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Single Arm

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved